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Background: There is a paucity of information on the differential effects of systemic versus
inhaled corticosteroids on airway inflammation in patients with acute asthma. This study
aimed to evaluate the effects of stopping systemic corticosteroids while maintaining the
inhaled corticosteroids (ICS) on airway inflammation, lung function and asthma symptoms in
patients who had been discharged from hospital after treatment for severe acute asthma.
Methods: Twenty-four adult patients with severe exacerbations of asthma were treated with
both oral and inhaled corticosteroids after discharge from hospital. Oral corticosteroids were
stopped after 1 week. Spirometry, asthma quality of life questionnaire (AQLQ) score and
exhaled nitric oxide (NO) were measured at discharge, 1 week, and 2 weeks after discharge.
Results: Withdrawal of oral corticosteroids resulted in significant rebound in mean exhaled NO
by 11.0 ppb (95% CI, 4.9e17.1 ppb, p < 0.001) or 47.7% (95% CI, 22.4e73.1%) despite uninter-
rupted ICS treatment. The rebound in exhaled NO occurred despite significant improvement in
the mean AQLQ score (pZ 0.006) and frequency of reliever use (pZ 0.003) and was not asso-
ciated with significant change in the mean FEV1 (pZ 0.64).
Conclusions: In patients discharged from hospital after treatment for asthma exacerbations,
withdrawal of oral corticosteroids resulted in increase in exhaled NO levels despite continued
ICS treatment.
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Measurement of exhaled nitric oxide (NO) is a non-invasive
test for detection of endogenous inflammatory signals in
patient with asthma.1 Elevated levels of exhaled NO have
been documented in patients with asthma.2,3 Exhaled NO
levels are further increased during asthma exacerbations,4,5
and fall following treatment with inhaled6 and systemic
corticosteroids.4 Oral prednisolone reduces exhaled NO in.
Figure 1 Measurements done at discharge, visit 1 (1 week
after discharge from hospital) and visit 2 (2 weeks after
discharge from hospital). Definition of abbreviations: ENOZ
exhaled nitric oxide; FEV1Z forced expiratory volume in 1 s;
AQLQZ asthma quality of life questionnaire score.
Effects of inhaled versus systemic corticosteroids on exhaled NO 615infants and young children with wheezing exacerbations.5 In
children with more severe asthma, oral corticosteroids shift
their exhaled NO down to the levels of mild-to-moderate
asthmawith accompanying improvement in lung function.7 A
combination of oral prednisolone and inhaled corticosteroids
(ICS) reduces exhaled NO by 65% in children with acute
asthma.8However, there is an absenceof prospective studies
that evaluate the differential effects of inhaled versus
systemic corticosteroids on exhaled NO, lung function and
asthma symptoms in patients with acute asthma.
Sippel and coworkers, in a cross-sectional study, showed
that exhaled NO levels were significantly correlated with
markers of asthma control such as asthma symptoms,
dyspnoea score, use of rescue medication and reversibility
of airflow obstruction.9 Jones and colleagues showed that
elevation in exhaled NO levels was a useful early indicator
of loss of asthma control following withdrawal of ICS
treatment.10 A similar trend has been observed after
withdrawal of leukotriene receptor antagonists.11 Further-
more, exhaled NO appears to be sensitive to changes in
corticosteroids treatment, even in the absence of lung
function responses.12 These findings suggest that exhaled
NO may be related to asthma control and corticosteroids
treatment, and that serial exhaled NO measurements in
individual patients over time may be useful in the adjust-
ment of anti-inflammatory treatment. Although exhaled NO
has been used to monitor the effect of anti-inflammatory
treatment in asthma6,13 and asthma exacerbations,4,12
there is a lack of prospective serial studies of exhaled NO,
together with lung function, asthma symptoms and asthma
relapse. The utility of serial exhaled NO measurements in
patients with acute asthma after completion of systemic
corticosteroids treatment, when they are at risk of relapse
and re-admissions, has not been studied previously.
The aim of our study was to evaluate the effects of
stopping systemic corticosteroids while maintaining the ICS
on the exhaled NO levels, lung function and asthma symp-
toms in patients who have been discharged from hospital
after treatment for acute severe asthma.
Materials and methods
Study subjects
Adult patients admitted to the Medical Department of
a university hospital with acute exacerbations of asthma
were invited to participate in the study. All patients were
non-smokers, had prior diagnosis of asthma and had pre-
sented with symptoms consistent with acute exacerba-
tions to the Emergency Department. Asthma was
diagnosed based upon a history of episodic respiratory
symptoms, a prior physician’s diagnosis of asthma, the use
of inhaled asthma therapy and pulmonary function testing
prior to the exacerbation which demonstrated at least
15% improvement in FEV1 following bronchodilator
therapy. Acute exacerbations were defined as increasing
symptoms requiring emergency treatment and presenta-
tion to the hospital. Ethical approval was obtained from
the National Healthcare Group (NHG) Ethics Committee
and informed consent was obtained from all study
participants.Study design
Patients who did not respond adequately to therapy insti-
tuted in the Emergency Department were admitted to
hospital for inpatient treatment of acute asthma. Research
nurse was contacted to screen for eligibility, obtain
informed consent and complete clinical asthma question-
naire. During the inpatient period, all patients received
standard treatment for acute asthma, which consisted of
5 mg of nebulized salbutamol and 500 mg of ipratropium
bromide every 6 h for the first 24 h and systemic cortico-
steroids in the form of oral prednisolone of 0.5 mg/kg.
Patients were also maintained on their usual dose of ICS.
Decision to discharge patients from hospital was made by
the attending physicians based on symptom resolution and
lung function.
On the day of discharge, all patients were continued on
ICS and prescribed a non-tapering course of prednisolone of
0.5 mg/kg per day for 1 week. Spirometry and exhaled NO
were measured on the day of discharge. Spirometry,
exhaled NO and asthma quality of life questionnaire (AQLQ)
were measured at visit 1 (1 week after discharge, when the
patients had been on both oral prednisolone and inhaled
corticosteroids) and at visit 2 (2 weeks after discharge,
when the patients had been on maintenance ICS only).
Measurements obtained at each visit are shown in Figure 1.
Patients were instructed to keep diaries on the frequency
of reliever use. All patients were contacted by a research
nurse by telephone after hospital discharge to reinforce
compliance with asthma medications. They were also con-
tacted monthly for 3 months after hospital discharge to
obtain information relating to relapses which required
commencement of systemic corticosteroids, increase in
maintenance dose of inhaled corticosteroids, unscheduled
visits to doctors or hospital admissions.
Exhaled NO level was measured according to the 1999
American Thoracic Guidelines,14 using a nitric oxide
Figure 2 Exhaled nitric oxide (ENO) measurements at
discharge, visit 1 and visit 2. ENO decreased significantly after
treatment with oral and inhaled steroids (visit 1). ENO
increased significantly after withdrawal of oral steroids despite
the uninterrupted inhaled steroids treatment (visit 2). Defini-
tion of abbreviations: ENOZ exhaled nitric oxide; ICSZ in-
haled corticosteroids.
Figure 4 Asthma quality of life questionnaire (AQLQ) scores
at visit 1 and visit 2. With uninterrupted inhaled steroids
treatment, AQLQ scores improved significantly despite with-
drawal of oral steroids.
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expiratory flow rate of 50 mL/s.
Forced expiratory volume in 1 s (FEV1) and forced mid-
expiratory flow rate (FEF25e75%) were measured according
to American Thoracic Society standards15 and the best
value of three maneuvers was expressed as a percentage of
the predicted value for the local population.16
A disease-specific quality of life measure, the Asthma
Quality of Life Questionnaire (AQLQ),17 was used in this
study. The instrument has been validated and demon-
strated to be responsive to change.18 The minimal clinically
important difference is a change in score of 0.5 (on a scale
of 7).19Figure 3 FEV1 (% predicted) at discharge, visit 1 and visit 2.
FEV1 improved significantly after treatment with oral and
inhaled steroids (visit 1). No significant change in FEV1 after
withdrawal of oral steroids (visit 2). Definition of abbrevia-
tions: FEV1Z forced expiratory volume in 1 s; ICSZ inhaled
corticosteroids.Statistical analysis
Continuous variables are expressed as mean  standard
deviation unless otherwise specified. One-factor repeated
measures ANOVA with adjustment for multiple comparison
(Bonferroni) was used to compare the exhaled NO levels,
FEV1 and FEF25e75% at discharge, visit 1 and visit 2. Stu-
dent’s paired t-test was used to compare AQLQ scores
between visit 1 and visit 2. Wilcoxon Signed Ranks test was
used to compare the paired data on frequency of reliever
use between visit 1 and visit 2. P values of <0.05 were
considered statistically significant.
Results
Twenty-four patients entered the study (a total of 30
patients were approached for the study, of whom six
declined to participate). Demographic data are given in
Table 1. None of the patients were on nasal corticosteroids.Figure 5 Average daily frequency of reliever use in the
weeks prior to visit 1 and visit 2. With uninterrupted inhaled
steroids treatment, frequency of reliever use decreased
significantly despite withdrawal of oral steroids.
Table 1 Subjects’ characteristics
Age, mean (range) 39 (18e65) year
Male/female 9/15
Duration of asthma, mean (range) 15.9 (4e33) year
Asthma therapy n (%)
Budesonide 800 mg per day and
short-acting b2-agonist
11 (46)
Beclometasone 400 mg per day
and short-acting b2-agonist
7 (29)
Fluticasone 500 mg per day
and short-acting b2-agonist
5 (21)
Fluticasone 500 mg per day
and long-acting b2-agonist
1 (4)
Length of stay, mean (SD) 2.0 (1.2) days
FEV1 at discharge, mean (SD) 73.9 (20.0) % predicted
ENO at discharge, mean (SD) 60.3 (46.3) ppb
Effects of inhaled versus systemic corticosteroids on exhaled NO 617The mean (SD) exhaled NO level and FEV1 on the day of
discharge from hospital were 60.3  46.3 ppb and
73.9  20.0% predicted respectively. Average length of stay
was 2.0 days (range, 1e5 days). All patients had been
treated with ICS for persistent asthma prior to the exac-
erbations. None of the patients reported relapse of asthma
exacerbations which resulted in commencement of
systemic corticosteroids, increase in maintenance dose of
inhaled corticosteroids, unscheduled visits to doctors or
hospital admissions in the 3 months after discharge from
hospital.
Exhaled nitric oxide
The mean exhaled NO level on the day of discharge from
hospital was 60.3  46.3 ppb. Combined treatment with
systemic and inhaled corticosteroids over 7 days was asso-
ciated with a significant decrease in the mean exhaled NO
levels by 24.2 ppb (95% CI, 6.5e41.8 ppb, pZ 0.005) or
31.3% (95% CI, 16.3e46.2%) from baseline. Withdrawal of
systemic corticosteroids resulted in a rebound of the mean
exhaled NO level by 11.0 ppb (95% CI, 4.9e17.1 ppb,
p < 0.001) or 47.7% (95% CI, 22.4e73.1%) despite the
continued ICS treatment (Fig. 2).
Pulmonary function, quality of life and frequency
of reliever use
At discharge from hospital, the mean FEV1 was 73.9  20.0%
predicted. At visit 1, the mean FEV1 improved significantly
by 13.6% predicted (95% CI, 5.8e21.4%, p < 0.001) after
treatment with both systemic and inhaled corticosteroids
for 7 days (Fig. 3). At visit 2, 1 week after the withdrawal of
the systemic corticosteroids, the mean FEV1 showed
a continued but non-significant improvement of 2.3%
predicted (95% CI, 2.3 to 6.9, pZ 0.64). FEF25e75%
measurements showed a trend that was similar to that of
FEV1. The mean FEF25e75% improved by 17.8% predicted (95%
CI, 5.8e29.9%, pZ 0.003) between discharge and visit 1,
but did not show any significant change between visit 1 and
visit 2 (0.12% predicted; 95% CI, 8.0 to 7.7%, pZ 1.00).AQLQ scores improved significantly by 0.53 (95% CI,
0.17e0.88, pZ 0.006) between visit 1 and visit 2 (Fig. 4).
Frequency of reliever use (Fig. 5) also decreased signifi-
cantly despite the withdrawal of systemic corticosteroids
and rebound in exhaled NO levels (pZ 0.003).Discussion
The novel finding of this study was that in patients dis-
charged from hospital after treatment for severe acute
asthma, withdrawal of oral corticosteroids resulted in
rebound of exhaled NO levels despite continued ICS treat-
ment. These changes in exhaled NO were not accompanied
by worsening of lung function or asthma symptoms.
There are a few possible explanations for our observa-
tions. First, the increase in exhaled NO levels may be
a reflection of a peripheral component of airway inflam-
mation that is less influential or has a delayed effect on
lung function and asthma symptoms. The rebound in
exhaled NO levels despite uninterrupted ICS treatment may
be a result of the inability of ICS to penetrate beyond
smaller distal airways. It is possible that ICS are able to
suppress inducible NO synthase in the larger airways but
unable to reach the distal airways to have effects on the
peripheral parenchymal inflammation. Lehtimaki et al. had
used the two-compartment model described by Tsoukias
and George,20,21 and found that alveolar NO concentration
was increased in asthmatic patients with nocturnal symp-
toms.22 The same group also observed that inhaled fluti-
casone decreased bronchial NO flux but had no effect on
alveolar NO concentration.23 Gelb et al. reported increased
alveolar NO concentration in patients with clinically stable
asthma despite treatment with ICS.24 Five days of 30 mg
prednisone resulted in isolated significant decrease in
alveolar NO concentration. Results from these studies
suggest the presence of inflammation in very distal gas
exchanging respiratory bronchioles and alveoli in asthmatic
patients.24
There is an increasing body of evidence that there may
be a concomitant lung parenchymal component in asthma.
Kraft et al. reported the presence of inflammatory cells in
the lung parenchyma obtained by fiberoptic bronchoscopy
biopsy in patients with nocturnal asthma.25 Gelb et al.
reported unexplained loss of lung parenchymal elastic
recoil properties not due to emphysema in stable, non-
smoking, patients with chronic persistent asthma with
abnormal expiratory airflow limitation.26,27 Berry et al.
found that alveolar NO were elevated in patients with
refractory asthma and reduced by oral prednisolone treat-
ment.28 Belda et al. reported that in patients with acute
asthma, oral prednisone reduced blood eosinophil counts,
while inhaled fluticasone reduced airway eosinophil counts,
suggesting that the anti-inflammatory performance of
inhaled fluticasone is exerted locally.29 The findings of the
present study may be related to the presence of a separate
component of peripheral inflammation in patients with
acute exacerbation of asthma that is not suppressed by ICS.
Second, changes in exhaled NO level may precede other
parameters such as lung function and may therefore serve
as an early warning of loss of control. Previous studies
have yielded inconsistent data regarding the correlation
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asthma control.4,8,30 Kharitonov and colleagues have
described exhaled NO as a ‘‘rapid response’’ marker, which
is extremely sensitive to corticosteroid treatment as it may
be significantly reduced even after 6 h following a single
treatment with nebulized corticosteroids, or within 2e
3 days after inhaled corticosteroids, reaching maximal
effect after 2e4 weeks of treatment.31 A possible expla-
nation for our finding is, therefore, that our patients had
indeed had early sub-clinical airway inflammation, which
was detected only by exhaled NO measurements following
oral corticosteroids withdrawal. However, the absence of
exacerbations in the 3 months after hospital discharge in all
twenty-four patients suggests that these early signals of
occult airway inflammation may be of doubtful clinical
significance.
Third, our observations may be due to the dose-response
effects of corticosteroids on airway inflammation and
exhaled NO. It is possible that the rebound in exhaled NO
had resulted from the reduction in the total dose of corti-
costeroids received by the study subjects after withdrawal
of the oral corticosteroids. Previous studies have suggested
a dose-response relationship between exhaled NO and
ICS.32 However, these studies also found that a plateau
effect on exhaled NO was seen at a dose of 400 mg of
inhaled budesonide.32,33 In the present study, all the
subjects were maintained on ICS doses that were either
equivalent to or above 400 mg of budesonide, putting them
on the upper end of the dose-response curve. The rebound
in exhaled NO was more likely to be due to the differential
effect of oral corticosteroids withdrawal than the dose-
response effect of corticosteroids on exhaled NO since all
the subjects were maintained on the upper end of the dose-
response curve throughout the study period. In addition,
commencement of oral prednisone has been shown to
result in a decrease in exhaled NO in patients with asthma
who were already on ICS, suggesting a separate effect of
oral corticosteroids that may not be related to the dose-
response relationship.24,28 The differential effects of
inhaled versus systemic corticosteroids on the three
components of asthma: airway inflammation, lung function
and clinical symptoms in patients with acute asthma are
still unclear.
Finally, it is possible that our observations had resulted
from the isolated effects of corticosteroids on exhaled NO
and were unrelated to airway inflammation. Corticosteroids
have been shown to reduce exhaled NO by directly inhib-
iting the induction of nitric oxide synthase 2 (NOS2).34 The
increase in exhaled NO levels after withdrawal of oral
corticosteroids may have been the result of a loss of direct
inhibition of NOS2 by systemic corticosteroids and not the
removal of suppression of pro-inflammatory cytokines.
Results of the present study have two important clinical
implications. First, exhaled NO may have limited clinical
utility as a marker to guide anti-inflammatory therapy in
the period immediately after asthma exacerbations when
patients are at risk of relapse. The lack of concordant
response between exhaled NO and other measures of
asthma control suggests that exhaled NO level is highly
sensitive to variations in oral corticosteroid treatment and
may not be a useful indicator of response to treatment
during recovery from acute exacerbations of asthma inpatients who are on ICS. Recommencement of oral corti-
costeroids or escalation in the dose of ICS in our patients in
response to the increase in exhaled NO levels may have
resulted in over-treatment with corticosteroids. Second,
the presence of a component of inflammation that is not ICS
responsive, if confirmed by further studies, challenges the
role of ICS in the management of acute asthma.23,24,28 An
emerging area of study is the role of ICS in the treatment of
acute asthma. Trials in which ICS were compared with
placebo demonstrated clear beneficial effects of ICS. In
contrast, the evidence was conflicting in trials where ICS
were compared with systemic corticosteroids.35 These
findings may be related to the presence of peripheral
inflammation that is suppressed by systemic corticosteroids
but not ICS. The characteristics, anatomic site and clinical
significance of this component of airway inflammation need
clarification with further studies.
Although our findings suggest a lack of concordant
response between exhaled NO and other measures of
asthma control in patients treated for acute asthma, the
results must be interpreted with caution. First,
the discordant relationship observed may have been due to
the small sample size. However, the consistent trend of
improvement observed in lung function and asthma symp-
toms suggests the presence of a genuine discordant rela-
tionship between the inflammatory signals and lung
function. Second, a parallel study design with a control
arm may have provided a better design to investigate the
effect of oral corticosteroids withdrawal. However,
a parallel design would have required some of the study
subjects to be continued on oral prednisolone beyond
1 week despite improvement in all the conventional
measures of asthma control (lung function, clinical symp-
toms and frequency of reliever use). The fact that the
study subjects were maintained on relatively high doses of
ICS (upper end of the dose-response curve) throughout the
study period and the consistent trend of rebound in
exhaled NO suggest the presence of a significant exhaled
NO signal associated with oral corticosteroids withdrawal.
Third, exhaled NO levels, lung function and asthma symp-
toms were monitored in the setting of uninterrupted
maintenance ICS treatment in the present study. This may
hence limit generalization of the results to patients who
are not on maintenance ICS after acute exacerbations.
Fourth, we did not perform sputum eosinophils count or
bronchial biopsy to ascertain the presence of airway
inflammation. However, the observed improvement in lung
function, asthma symptoms and the absence of relapse in
the follow up period suggest the absence of clinically
important airway inflammation that requires escalation of
anti-inflammatory treatment.
In conclusion, we found that in patients discharged from
hospital after treatment for severe asthma exacerbations,
withdrawal of oral corticosteroids resulted in an increase in
exhaled NO levels despite continued ICS treatment. The
increase in exhaled NO was not accompanied by reduction
in lung function and occurred despite improvement in AQLQ
scores and rescue medication use. The differential effects
of inhaled versus systemic corticosteroids on different
sources of exhaled NO and their relationships with different
components of airway inflammation need further investi-
gations and clarifications.
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Originality and clinical relevance
There is a paucity of data on the differential effects of
inhaled versus systemic corticosteroids on airway inflam-
mation, lung function and asthma symptoms in patients
with severe acute asthma. Our study found that withdrawal
of oral corticosteroids resulted in an increase in exhaled NO
levels despite continued inhaled corticosteroid treatment.
There was also a discordant relationship between exhaled
NO, lung function and clinical symptoms. Our results may
have important clinical implications relating to: (1) the
clinical utility of exhaled NO in patients with acute asthma;
and (2) the effects of inhaled corticosteroids on airway
inflammation in acute asthma.Acknowledgements
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